A5028533961- Chronic Lymphocytic Leukemia Research
- Lymphoma Diagnosis and Treatment
- Immunodeficiency and Autoimmune Disorders
- Glycosylation and Glycoproteins Research
- Monoclonal and Polyclonal Antibodies Research
- Immune Cell Function and Interaction
- Cancer-related Molecular Pathways
- Acute Lymphoblastic Leukemia research
- Phagocytosis and Immune Regulation
- Galectins and Cancer Biology
- Nanoparticle-Based Drug Delivery
- Calcium signaling and nucleotide metabolism
- Advanced Breast Cancer Therapies
- Cancer, Hypoxia, and Metabolism
- RNA modifications and cancer
- CAR-T cell therapy research
- Immunotherapy and Immune Responses
- Cancer Genomics and Diagnostics
- Cell Adhesion Molecules Research
- Cancer-related molecular mechanisms research
- Advanced biosensing and bioanalysis techniques
- Ferroptosis and cancer prognosis
- RNA Interference and Gene Delivery
- Cancer Immunotherapy and Biomarkers
- Viral-associated cancers and disorders
Centro di Riferimento Oncologico
2016-2025
Istituti di Ricovero e Cura a Carattere Scientifico
2015-2025
University of Bologna
2004-2010
Università degli Studi del Piemonte Orientale “Amedeo Avogadro”
2010
University of Siena
2010
University of Modena and Reggio Emilia
2010
Zero to Three
2008
St. Eugenio Hospital
2006
University of Rome Tor Vergata
2004
Kobe University
1985
CD38 and CD49d are associated negative prognosticators in chronic lymphocytic leukemia (CLL). Despite evidence that both molecules involved interactions occurring between CLL normal cells the context of CLL-involved tissues, a functional link is still missing. Using gene expression profiles comparing CD38(+)CD49d(+) versus CD38(-)CD49d(-) cells, we showed overexpression CCL3 CCL4 chemokines from former group. These were also up-regulated by signals CLL; moreover, was expressed bone marrow...
The Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib, which antagonizes B cell receptor (BCR) signals, demonstrates remarkable clinical activity in chronic lymphocytic leukemia (CLL). lymphocytosis experienced by most patients under ibrutinib has previously been attributed to inhibition of BTK-dependent integrin and chemokine cues operating retain the tumor cells nodal compartments. Here, we show that VLA-4 integrin, as expressed CD49d-positive CLL, can be inside-out activated upon BCR...
About 50% of cutaneous melanoma (CM) harbors the activating BRAFV600 mutation which exerts most oncogenic effects through MAPK signaling pathway. In last years, a number modulators have been identified, including Spry1. this context, we recently demonstrated that knockout Spry1 (Spry1KO) in BRAFV600-mutant CM led to cell cycle arrest and apoptosis, repressed proliferation vitro, reduced tumor growth vivo. Despite these findings, however, precise molecular mechanism linking remains be...
A fraction of chronic lymphocytic leukaemia (CLL) cases carry highly homologous B-cell receptors (BCR), i.e. characterized by non-random combinations immunoglobulin heavy-chain variable (IGHV) genes and complementarity determining region-3 (HCDR3), often associated with a restricted selection IGVK/L light chains. Such 'stereotyped' BCR occur more frequently in CLL unmutated (UM) than mutated (M) IGHV genes. We analysed 1426 IG rearrangements (from 1398 cases) clustering driven HCDR3...
Abstract Deletion at 13q14 is detected by fluorescence in situ hybridization (FISH) about 50% of chronic lymphocytic leukemia (CLL). Although CLL with 13q deletion as the sole cytogenetic abnormality (del13q‐only) usually have good prognosis, more aggressive clinical courses are documented for del13q‐only carrying higher percentages deleted nuclei. Moreover, different sizes been described, whose prognostic significance still unknown. In a multi‐institutional cohort 342 cases and consecutive...
In chronic lymphocytic leukemia the balance between pro-apoptotic and anti-apoptotic members of bcl-2 family is involved in pathogenesis, chemorefractoriness clinical outcome. Moreover, recently proposed anti-bcl-2 molecules, such as ABT-199, have emphasized potential role proteins context target therapies. We investigated bax/bcl-2 ratio by flow cytometry 502 patients identified a cut off 1.50 to correlate with well-established biological prognosticators. Bax/bcl-2 was or over 263 (52%)...
In chronic lymphocytic leukemia (CLL), the hypoxia-inducible factor 1 (HIF-1) regulates response of tumor cells to hypoxia and their protective interactions with leukemic microenvironment. this study, we demonstrate that CLL from TP53-disrupted (TP53dis) patients have constitutively higher expression levels α-subunit HIF-1 (HIF-1α) increased transcriptional activity compared wild-type counterpart. TP53dis subset, HIF-1α upregulation is due reduced ubiquitin ligase von Hippel-Lindau protein...
Poly-N-Vinylcaprolactam (PNVCL) is a thermoresponsive polymer that exhibits lower critical solution temperature (LCST) between 25 and 50 °C. Due to its alleged biocompatibility, this becoming popular for biomedical environmental applications. PNVCL with carboxyl terminations has been widely used the preparation of copolymers, micro- nanogels drug delivery oncological therapies. However, fabrication such specific targeting devices needs standardized reproducible methods. This requires deep...
Over the past two decades, Next-Generation Sequencing (NGS) has revolutionized approach to cancer research. Applications of NGS include identification tumor specific alterations that can influence pathobiology and also impact diagnosis, prognosis therapeutic options. Pharmacogenomics (PGx) studies role inheritance individual genetic patterns in drug response taken advantage technology as it provides access high-throughput data can, however, be difficult manage. Machine learning (ML) recently...
Multiple myeloma (MM) is an incurable hematological disease characterized by the uncontrolled growth of plasma cells primarily in bone marrow. Although its treatment consists administration combined therapy regimens mainly based on immunomodulators and proteosome inhibitors, MM remains incurable, most patients suffer from relapsed/refractory with poor prognosis survival. The robust results achieved immunotherapy targeting MM-associated antigens CD38 CD319 (also known as SLAMF7) have drawn...